Source: Lawyers Collective | 12 March 2018
Survivors of drug resistant tuberculosis, health organisations and the TB community in India and across the globe have appealed to the Prime Minister of India to issue a government use compulsory license for two of the essential drugs for Drug-Resistant Tuberculosis (DR-TB) treatment- Bedaquiline and Delamanid to encourage generic competition.
Bedaquiline and Delamanid adult formulations were added to the WHO Essential Medicines List (EML) for TB in 2015, and Delamanid was added to the WHO EML for children in 2017. Continue reading
Source: PTI Published: India Today | March 13, 2018
New Delhi: Survivors of drug-resistant tuberculosis, health organisations and the TB community have appealed to Prime Minister Narendra Modi to allow issuance of compulsory licence for two of the essential drugs for drug-resistant TB (DR-TB) treatment so that Indian drug-makers can sell them at affordable prices.
Bedaquiline and Delamanid are recommended by the World Health Organisation (WHO) for DR-TB patients. Continue reading
DRUG ACTION FORUM – KARNATAKA
57, Tejaswinagar, Dharwad 580002. 0836-2461722
(Registered, independent NGO campaigning for Rational Drug Therapy and Policies)
Date 9th March 2018
The Prime Minister, New Delhi. email@example.com
Subject;- Granting of CL for Bedaquiline and Delaminid
We the undersigned learn from media report that two important drugs (Bedaquiline and Delaminid manufactured by Janssen of the USA and Otsuka of Japan) needed to treat Drug Resistance Tuberculosis (DR TB) are not available to Indian patients. Both the drug companies are ready to donate the medicines but it well known from previous experiences that such “donations” are only an excuse for the drug companies to tighten the grip over market and thus keep the drug price high. This will only keep the medicines away from the reach of the needy. Unfortunately the drug manufacturing companies are not even ready for voluntary licensing. Continue reading
by Andrew Goldman, Knowledge Ecology International | 8 March 2018
In a resolution dated the 9th of March, 2018, Minister Carmen Castillo Taucher of Chile’s Ministry of Health has announced that there are sufficient public health reasons to support a compulsory license on medicines for the hepatitis C virus (HCV), as requested by Corporacion Innovarte, Fundacion Renacer, members of the Chilean Congress including Giorgio Jackson, Karla Rubilar, Miguel Angel Alvarado, and Gabriel Boric, and patients in March 2017. The announcement is Ordinario A15 No.1135, and the formal resolution is here.
A government review says it is well within its rights to put Indian patients and the Indian generic pharmaceuticals industry first.
As various countries await the US’s ‘Special 301 report’, where the US government discusses intellectual property negotiations with other countries, , the Indian government has published a report of its on the same topic, affirming its sovereign commitments to India’s generic drugs industry and healthcare. Continue reading
By Son Ji-hyoung, The Korea Hearld
South Korea has submitted a document hitting back at a claim by a US trade group representing its pharmaceutical industry that Korea’s drug pricing policies favor its domestic industry, ministries said Wednesday.
The document was prepared by the Ministry of Health and Welfare and submitted Thursday to the US Trade Representative, a US counterpart in the bilateral free trade deal, by the Ministry of Trade, Industry and Energy, according to a ministry spokesperson. Continue reading
Jason Cone | The Hill
The White House Council of Economic Advisers recently announced a strategy to curb high drug prices: force “free riding” countries abroad to pay more and watch the prices go down in America.
That’s not how it works; lifesaving medicines aren’t more expensive here because they cost less elsewhere. They’re priced out of reach everywhere because pharmaceutical corporations are charging exorbitant prices simply because they can—and the U.S. government lets them. Continue reading